Biogen Idec Total Revenues Increased 10% to $1.4 Billion in First Quarter 2013 MarketWatch (press release) On April 4, 2013, Biogen Idec announced results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial were published in an on-line article in The Lancet. SELECT was a Phase 2b registrational study designed to determine the efficacy and ... |
